IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Sanofi v Amgen Inc. [2018] APO 3
Patent Applications: 2013203677
2013203748
2013203685
2013203689
2013203751
Title:Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) [each application has the same title]
Patent Applicant: Amgen Inc.
Opponent: Sanofi
Hearing Officer: Dr S.D. Barker – Deputy Commissioner of Patents
Decision Date: 11 January 2018
Hearing Date: 9 January 2018, in Canberra
Catchwords: PATENTS – section 210 – request for production of documents – whether the documents are likely to be of substantial relevance to the matter – request refused
Representation: Patent attorneys for the applicant: Gary Cox and Dr Linda Kennaugh of Wrays
Counsel for the opponent: David Shavin QC
Legal representatives for the opponent: Lisa Taliadoros and Anthony Muratore of Jones Day
IP AUSTRALIA
AUSTRALIAN PATENT OFFICE
Patent Applications: 2013203677
2013203748
2013203685
2013203689
2013203751
Title:Antigen Binding Proteins to Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) [each application has the same title]
Patent Applicant: Amgen Inc.
Date of Decision: 11 January 2018
DECISION
I refuse the request for the Commissioner to order production of documents under section 210.
REASONS FOR DECISION
This matter concerns requests by Sanofi for orders under section 210 of the Patents Act 1990 (the Act) for the production of documents for the purpose of five oppositions under section 59.
Background
Patent application 2008288791 was filed in the name of Amgen Inc. (Amgen) on 22 August 2008, and has now proceeded to grant. Five divisional applications were filed on 11 April 2013: 2013203677, 2013203748, 2013203685, 2013203689 and 2013203751 (the present applications). The present applications were accepted and grant of each application has been opposed by Sanofi. Evidence in answer has been completed in each opposition.
As part of the evidence in answer of each opposition, evidence was provided by Professor Petsko. Professor Petsko's evidence included a consideration of the crystal structure of various products identified as PCSK9/31H4, PCSK9/21812/31H4,PCSK9/8A3, PCSK9/11F1, PCSK9/1A12, PCSK9/25G4 and PCSK9/EGFa. This task involved the use of computer files (known as .pdb files) using the PyMOL program. Professor Petsko declared that Amgen provided him with copies of the .pdb files. Professor Petsko's evidence included copies of the information in the .pdb files in the form of .txt files in PDF format.[1]
[1] The PyMOL program is an X-ray crystallography data imaging program. PyMOL uses atomic coordinates data in a file that has the extension .pdb. Amgen has stated in correspondence dated 13 November 2017 that the .txt files provided by Professor Petsko can be converted to .pdb files that can be used by the PyMOL program by changing the file extension from .txt to .pdb.
Prior to filing Professor Petsko's evidence Amgen had sought a direction from the Commissioner that it be allowed to file .pdb files and that those files be treated as confidential. The Commissioner declined to provide the direction.
On 3 November 2017 Sanofi requested that the Commissioner issue a notice to Amgen to produce the .pdb files used by Professor Petsko. A…
Keep reading for free
Create a free CaseChat account to read Sanofi v Amgen Inc and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2018] APO 3
- Decision Date
CaseChat Overview and Summary
The legal issue before the court was whether the Commissioner had the authority to order the production of the.pdb files under section 210 of the Patents Act 1990. Section 210 allows the Commissioner to require the production of documents if they are likely to be of substantial relevance to the matter before the Commissioner. The court considered whether Sanofi had demonstrated that the.pdb files were likely to be of substantial relevance, given that the.txt files provided to Sanofi were already in evidence.
The court found that Sanofi had not provided sufficient evidence to show that the.pdb files were materially different from the.txt files already in their possession. The court also noted that the power to require the production of documents under section 210 is discretionary and should not be used for exploratory purposes. The court concluded that there was no substantial relevance in producing the original.pdb files, as the .txt files provided were sufficient for the proceedings.
The court declined to issue a notice to produce the.pdb files, ruling that Sanofi had not demonstrated a reasonable basis to believe that there was a material difference between the files. The court emphasised that the power under section 210 should only be exercised when there is a real and specific factual issue in dispute, and the documents are likely to be highly significant in resolving the matter.
Background
Background to the litigation
Sanofi filed requests for orders under section 210 of the Patents Act 1990 to compel the production of the.pdb files used by Professor Petsko. The Senior Examiner at IP Australia initially declined the request, finding that production would substantially replicate information already in evidence. Amgen provided a set of.pdb files on a thumb drive, which the Commissioner made available to Sanofi. Despite this, Sanofi persisted with their request for a notice to produce the.pdb files. The matter was heard by Dr S.D. Barker, Deputy Commissioner of Patents, on 9 January 2018, with Amgen appearing by telephone.
Decision
Reasons for decision
1. Whether the Commissioner should order the production of the.pdb files under section 210 of the Patents Act 1990.
2. Whether there is a substantial relevance in producing the.pdb files for the purposes of the oppositions.
Held
1. The court refused the request for the Commissioner to order production of documents under section 210 of the Patents Act 1990.
2. The court found there is no substantial relevance in producing the.pdb files for the purposes of the oppositions.
Ratio Decidendi
Legal Principle Established
The court considered the request for the Commissioner to order the production of the.pdb files under section 210 of the Patents Act 1990. The court noted that Sanofi had requested the production of the.pdb files used by Professor Petsko, who provided evidence in the oppositions, based on the concern that there is a material difference between the.txt file in evidence and the.pdb file given to Professor Petsko. The court examined the language used by Professor Petsko in his evidence, which stated that the.txt file contains the same coordinates as found in the.pdb file and provides the R-value and R-free metrics for the structure. The court concluded that there is no reasonable inference that the.txt file is materially different to the.pdb file, and thus there is no substantial relevance in producing the.pdb files. The court also noted that the request for production under section 210 is not to be invoked as a general means of exploring the other party’s case and is not to be used in a fishing expedition or a hunt for a'smoking gun'. The court applied the reasoning and conclusions of the Deputy Commissioner in Domino's Pizza Enterprises Limited v Precision Tracking Pty Ltd in relation to the operation of section 210. The court found that Sanofi had not demonstrated a reasonable basis to believe that there is (or that there could be) a material difference between the .pdb files used by Professor Petsko and the.txt files, and thus there is no denial of natural justice. The ratio decidendi of this case is that a request for production under section 210 of the Patents Act 1990 must meet a high threshold of substantial relevance, and the court must consider the degree of relevance in determining whether to grant the request.